Compounds for treatment of cancer

A compound of Formula IX having the structure

• wherein R4 and R5 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH2CN, NH2, hydroxyl, —(CH2)iNHCH3, —(CH2)iNH2, —(CH2)iN(CH3)2, —OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH2 or NO2;
• A′ is halogen;
• substituted or unsubstituted single-, fused- or multiple-ring, aryl or (hetero)cyclic ring systems;
• substituted or unsubstituted, saturated or unsaturated N-heterocycles;
• substituted or unsubstituted, saturated or unsaturated S-heterocycles;
• substituted or unsubstituted, saturated or unsaturated O-heterocycles;
• substituted or unsubstituted, saturated or unsaturated cyclic hydrocarbons;
• or substituted or unsubstituted, saturated or unsaturated mixed heterocycles;
• wherein said A′ ring is optionally substituted by 1-5 substituents which are independently O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CN, —CH2CN, NH2, hydroxyl, —(CH2)iNHCH3, —(CH2)iNH2, —(CH2)iN(CH3)2, —OC(O)CF3, C1-C5 linear or branched alkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH2 or NO2;
• i is an integer between 1-5;
• and
• n is an integer between 1-3;
• or its pharmaceutically acceptable salt, hydrate, polymorph, or isomer.